Ertugliflozin-d₅

Cat. No.:	HY-15461S	
CAS No.:	1298086-22-2	CI D
Molecular Formula:	C ₂₂ H ₂₀ D ₅ ClO ₇	
Molecular Weight:	441.91	ОН
Target:	SGLT	O O OH
Pathway:	Membrane Transporter/Ion Channel	ЮН
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.	НО

BIOLOGICAL ACTIVITY				
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as			

In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as	
	tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to	
	affect the pharmacokinetic and metabolic profiles of drugs $^{[1]}$.	
	MCE has not independently confirmed the accuracy of these methods. They are for reference only.	

REFERENCES

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.

[2]. Mascitti V, et al. Discovery of a clinical candidate from the structurally unique dioxa-bicyclo[3.2.1] octane class of sodium-dependent glucose cotransporter 2 inhibitors. J Med Chem. 2011 Apr 28;54(8):2952-60.

[3]. Miao Z, et al. Pharmacokinetics, metabolism, and excretion of the antidiabetic agent ertugliflozin (PF-04971729) in healthy male subjects. Drug Metab Dispos. 2013 Feb41(2):445-56.

[4]. Kalgutkar AS, et al. Preclinical species and human disposition of PF-04971729, a selective inhibitor of the sodium-dependent glucose cotransporter 2 and clinical candidate for the treatment of type 2 diabetes mellitus. Drug Metab Dispos. 2011 Sep39(9):1609-19.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

•

Proteins

MedChemExpress